Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 1, 2011, Pages 63-68

  Ku, J H ^a   Jeong, C W ^a   Park, Y H ^a   Cho, M C ^a   Kwak, C ^a   Kim, H H ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

biochemical outcome; HMG CoA reductase inhibitors; prostatectomy; prostatic neoplasm; statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KOREA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TREATMENT OUTCOME;

AGED; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KOREA; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79951671443     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.39     Document Type: Article

References (27)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
2. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363-2368.
3. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192. (Pubitemid 40727085)
4. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-19. (Pubitemid 36109711)
5. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942. (Pubitemid 41766782)
6. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005; 173: 1923-1925. (Pubitemid 40675212)
7. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1511-1518.
8. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825. (Pubitemid 46017933)
9. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213-2217. (Pubitemid 351196351)
10. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218-2225. (Pubitemid 351196352)
11. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterollowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226-2232. (Pubitemid 351196353)
12. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
13. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003; 27: 1291-1301. (Pubitemid 37185820)
14. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006; 164: 978-983. (Pubitemid 44729839)
15. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-545. (Pubitemid 46054056)
16. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003; 23: 1055-1069.
17. GraafMR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394. (Pubitemid 41115396)
18. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162: 318-325. (Pubitemid 41389713)
19. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO et al. Cancer risk among statin users: a populationbased cohort study. Int J Cancer 2005; 114: 643-647. (Pubitemid 40349625)
20. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250-260. (Pubitemid 352019786)
21. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477-1486. (Pubitemid 47572633)
22. Banez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010; 19: 722-728.
23. Soto DE, Daignault S, Sandler HM, Ray ME. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158-162.
24. Moyad MA, Merrick GS, Butler WM,Wallner KE, Galbreath RW, Kurko B et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66: 1150-1154. (Pubitemid 41797279)
25. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2653-2659.
26. Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ. Is statin use associated with prostate cancer aggressiveness? BJU Int 2010; 105: 1222-1225.
27. Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: 118-124.